GC
NBIX icon

Globeflex Capital’s Neurocrine Biosciences NBIX Stock Holding History

Globeflex Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.71M Sell
28,173
-1,341
-5% -$178K 0.56% 57
2025
Q4 		$4.19M Hold
29,514
– – 0.64% 53
2025
Q3 		$4.14M Buy
29,514
+1,057
+4% +$143K 0.64% 51
2025
Q2 		$3.58M Buy
28,457
+6,255
+28% +$717K 0.3% 78
2025
Q1 		$2.46M Sell
22,202
-1,202
-5% -$152K 0.23% 94
2024
Q4 		$3.19M Buy
23,404
+1,202
+5% +$149K 0.27% 87
2024
Q3 		$2.56M Buy
22,202
+703
+3% +$96.4K 0.25% 93
2024
Q2 		$2.96M Sell
21,499
-1,437
-6% -$197K 0.31% 73
2024
Q1 		$3.16M Hold
22,936
– – 0.31% 75
2023
Q4 		$3.02M Buy
22,936
+1,781
+8% +$205K 0.31% 80
2023
Q3 		$2.38M Hold
21,155
– – 0.28% 97
2023
Q2 		$1.99M Sell
21,155
-3,911
-16% -$382K 0.22% 116
2023
Q1 		$2.54M Buy
25,066
+7,828
+45% +$815K 0.31% 90
2022
Q4 		$2.06M Buy
17,238
+5,708
+50% +$669K 0.26% 97
2022
Q3 		$1.23M Buy
+11,530
New +$1.17M 0.21% 147
2020
Q4 		– Sell
-5,632
Closed -$542K – 505
2020
Q3 		$542K Sell
5,632
-999
-15% -$116K 0.14% 237
2020
Q2 		$809K Sell
6,631
-2,637
-28% -$291K 0.21% 168
2020
Q1 		$802K Hold
9,268
– – 0.25% 144
2019
Q4 		$996K Buy
+9,268
New +$970K 0.19% 192
2015
Q4 		– Sell
-20,400
Closed -$812K – 485
2015
Q3 		$812K Sell
20,400
-4,000
-16% -$193K 0.17% 211
2015
Q2 		$1.17M Buy
+24,400
New +$1.03M 0.21% 178

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Globeflex Capital's NBIX Position: Q1 2026 in Review

Globeflex Capital reduced its Neurocrine Biosciences (NBIX) stake by 4.5% in Q1 2026, selling an estimated $178K and leaving 28,173 shares worth $3.71M. The position accounts for 0.56% of the portfolio, ranked #57.

Globeflex Capital first reported a position in NBIX in Q2 2015 and has held it in 21 quarters since. The position peaked at $4.19M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Globeflex Capital held 28,173 shares of Neurocrine Biosciences worth $3.71M as of Q1 2026.
  • Globeflex Capital sold 1,341 Neurocrine Biosciences shares in Q1 2026, an estimated $178K.
  • Neurocrine Biosciences made up 0.56% of Globeflex Capital's portfolio in Q1 2026, its #57 holding.
  • Globeflex Capital first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 21 quarters since.
  • Globeflex Capital's Neurocrine Biosciences position peaked at $4.19M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.